Improved engraftment rates of AML samples have been achieved using NSG‐SGM3 (NSG humanized with SCF, GM‐CSF, and IL‐3) including cases where cells were from intermediate‐risk AML patients. This evidence concerns the gene KITLG and acute myeloid leukemia.